Yesterday,Medtronic (New YorkStock Exchange Code: MDT) Announces Voluntary Recall of Batteries for MiniMed 600 and 700 Series Insulin Pumps.The U.S. Food and Drug Administration (FDA) has confirmed this as a Class I recall.

Previously, Medtronic noted battery life issues earlier this year. In July, Medtronic sent a safety alert to customers, informing diabetes device users to follow the built-in alerts and battery status warnings. The company has now sent an updated letter detailing how the pump’s reduced battery life occurs and stating that customers should contact Medtronic if they observe changes in their pump's battery life.

Medtronic stated that it began investigating an issue after receiving reports of shortened battery life. A comprehensive analysis found,Even a single fall, collision, or physical impact may shorten the battery life of the pump.The company attributed this issue to the damage of internal electrical components.

When the remaining battery life is less than specified in the user guide, this electrical issue can also trigger a battery alarm. This may cause the insulin pump to stop insulin delivery much earlier than typically expected. In turn, this could lead to health risks such as hyperglycemia or diabetic ketoacidosis (DKA).

From January 2023 to September 2024,Medtronic received 170 reports of hyperglycemia (>400mg/dL) and 11 reports of diabetic ketoacidosis in the United States., all of which may be related to this issue.

According to Medtronic, even a single occurrence can lead to a shortened battery life, and the issue persists even after replacing the battery. The pump may still generate battery alerts and alarms, but they might not have the usual remaining battery life before needing replacement. The company advises users to always carry an extra set of new or fully charged batteries.

Medtronic Diabetes Chief Medical Officer Dr. Robert Vigersky said, "Our team is here 24 hours a day, 7 days a week. If you experience battery depletion or any other pump issue, we are here to help. Patient safety is our top priority, as is the continuity of therapy, which is why we have decided to voluntarily notify patients and replace pumps when needed."

This issue affects the MiniMed 600 series and 700 series. According to the FDA's deviceRecall Database, approximately 785,000 systems were related to the Class I recall in October.

Medtronic is a global leading medical technology company dedicated to providing lifelong treatment solutions for patients with chronic diseases. Its products cover multiple fields such as heart disease, neurological disorders, diabetes, and kidney diseases. The product range includes various medical devices, equipment, and related healthcare products, such as pacemakers, vascular stents, insulin pumps, etc.

As a medical technology company, Medtronic is also committed to researching and developing new medical technologies. The company has numerous R&D centers and production bases worldwide, with a total workforce of over 90,000 employees. Its operations are primarily divided into four main business groups: the Cardiovascular Business Group, the Medical Surgical Business Group, the Neuroscience Business Group, and the Diabetes Business Group, covering more than 150 countries and regions globally.

In March this year, Medtronic announced its third-quarter financial report for the fiscal year 2024, which ended on January 26.The report shows that the company's quarterly revenue was $8.1 billion (approximately 58.2 billion RMB), a year-on-year increase of 4.7%; the quarterly net profit was $1.34 billion, a year-on-year increase of 8.8%.

Screenshot from Medtronic's official website

Medtronic's organic revenue growth reflects the company's overall sustained momentum, primarily driven by strong growth in diabetes, core spine, cardiac surgery, structural heart, and cardiac rhythm management businesses, as well as its strength in international markets.

From the perspective of specific business units, all four of Medtronic's businesses achieved positive growth.The growth in diabetes business was the most significant (12.3%, $640 million); followed by cardiovascular (6.1%, $2.93 billion); neuroscience (4.3%, $2.36 billion) and medical surgical (3.9%, $2.15 billion), respectively.

Screenshot from Medtronic's official website

Medtronic Chairman and Chief Executive Officer Geoff Martha said, "As we once again firmly fulfill our commitments this quarter, our momentum is building. We continue to achieve sustainable revenue growth, performing exceptionally well across multiple business areas and international markets, as we expand the reach of innovative medical technologies worldwide. Our recent major product approvals – including transformative products in diabetes, cardiac rhythm management, neuromodulation, hypertension, and pulsed field ablation – strengthen our confidence in driving reliable growth over the next several quarters and years."

The diabetes sector is one of the rapidly growing engines of Medtronic's business, and the product subject to this recall is also one of its main products. How will Medtronic address and mitigate the impact of this recall? Medical Device News will continue to monitor the situation.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

China's First Pediatric Magnetoencephalography Joint Laboratory Established in Shanghai

"Chinese Version of Medtronic Officially Announced: Second-Generation Harvard Returnee Takes Over"

Fuwai and Anzhen Support: This High-End Medical Device Included in Medical Insurance

Over 30 Billion Yuan in Debt Pressure, Pharmaceutical Giant May Change Hands

China-produced Endoscopic Ultrasound Leader Completes New Round of Financing

Micromate® Single-Port Robot SP1000 Plus Debuts with World's First "Three-in-One" Solution

Multiple Hospitals: "Not Accepting Imported" Surgical Robots

Back to the Top! Shanhuaishan Hemodialysis Machine Market Share Remains Number One in the Industry

7.8 Billion, the Heavy Bet of the Ninth Largest Device Company

The King of Orthopedic Market Value, the Seventh Acquisition This Year

BusinessBusiness cooperation email: qxzj@landianyiliao.com